| News

CEO of Novartis pinning hopes on malaria drug

30.03.2020

In the fight against the coronavirus, Vas Narasimhan, CEO of Novartis, is above all pinning his hopes on a malaria drug. Narasimhan has claimed in an interview that this drug has proven in preclinical and initial clinical trials that it can destroy the virus. At the moment, patients are being enrolled for studies.

Vas Narasimhan, CEO of Novartis (img: Novartis)

In the opinion of Vas Narasimhan, the first wave of the coronavirus pandemic may have reached its peak in Spain and Italy, but will spread further in the USA. Now it is time to prepare for the next wave. The CEO of Basel-based Novartis is above all pinning his hopes on hydroxychloroquin, a drug used to treat malaria, which the company are focusing their work on.

“Preclinical trials in animals as well as initial data from clinical trials have shown that it destroys the coronavirus”, Narasimhan states in an interview with SonntagsZeitung. “We are working together with Swiss hospitals to check potential treatment protocols for clinical application, but it’s too early to offer anything definitive in this regard yet”, he adds. At the moment, the first patients are being recruited for enrolment in studies. Moreover, Novartis is in dialog with the regulatory authorities in Switzerland and the USA in order to obtain authorization by way of summary proceedings.

Novartis has at its disposal the raw material for 130 million doses. Export bans in India could, however, be an obstacle to production, Narasimhan explains. “Our plant in Stein AG would be the worst hit by export bans, as it currently procures raw materials on a global basis”. The pharma industry is reliant on the free flow of goods, with no country fully self-sufficient in this regard.

Together with 15 pharmaceutical firms from around the world in total, Novartis has committed its expertise to the Bill & Melinda Gates Foundation in the fight against the coronavirus pandemic. To this end, the group of pharma firms are to open up their proprietary libraries of molecular compounds to in the joint search for candidates to combat the virus.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Basel Area – exactly the right chemistry for South Korean pharma companies
Basel Area Business & Innovation, Innovation, Invest

Basel Area – exactly the right chemistry for South Korean pharma companies

KPBMA and Basel Area Business & Innovation establish tailored collaboration to support Korean biopharmaceutical companies to enter the European market

Read More
Basel Area supporting three digital health startups
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Basel Area supporting three digital health startups

Basel Area Business & Innovation will be offering intensive support to the three winners of its DayOne Digital Health Accelerator...

Read More
Gray establishes presence in Basel
Basel Area Business & Innovation, Innovation, Invest

Gray establishes presence in Basel

The North American fully integrated specialty service provider Gray has established a subsidiary in Basel. The key factors in favor...

Read More
Artificial Intelligence able to identify potentially life-saving antibiotics
Basel Area Business & Innovation, Innovation, Invest

Artificial Intelligence able to identify potentially life-saving antibiotics

A computer algorithm has identified antibiotics that that are still effective against infections in which multi-resistant germs are present. University...

Read More
Investors give Anaveon 110 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

Investors give Anaveon 110 million Swiss francs

Anaveon has received investment commitments amounting to 110 million Swiss francs in a Serie B funding round. The Basel-based biopharmaceutical...

Read More
Basel alliance seeks to combat antibiotic resistance
Basel Area Business & Innovation, Innovation, Invest

Basel alliance seeks to combat antibiotic resistance

The Spearhead alliance has been founded in Basel with the aim of combating the silent pandemic of antimicrobial resistance. By...

Read More
Kinarus and Noorik awarded federal grants
Basel Area Business & Innovation, Innovation, Invest

Kinarus and Noorik awarded federal grants

The Basel-based biopharmaceutical companies Kinarus and Noorik have been awarded federal grants for their clinical trials investigating drug candidates to...

Read More
Alloy acquires deepCDR and will expand Basel site
Basel Area Business & Innovation, Innovation, Invest

Alloy acquires deepCDR and will expand Basel site

Alloy Therapeutics, a biotechnology firm from Boston in the USA, has acquired the Basel-based startup deepCDR Biologics. Alloy labs and...

Read More
Basel Healthtech fund successfully closed
Basel Area Business & Innovation, Innovation, Invest

Basel Healthtech fund successfully closed

The venture capital firm MTIP has announced the successful closing of its FUND II. It is one of the first...

Read More
Roche tests able to detect Omicron
Basel Area Business & Innovation, Innovation, Invest

Roche tests able to detect Omicron

The Roche subsidiary TIB Molbiol has developed new coronavirus testing kits that can also detect the new Omicron variant of...

Read More
1 2 3 31

Do you have a question? We'd like to hear from you.